Brickell Biotech Announced Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Brickell Biotech Inc., a clinical-stage pharmaceutical company has been striving to transform the lives of the patient by developing the innovative and differentiated prescription therapeutics for the treatment of the autoimmune, inflammatory and several other diseases, has signed a purchase agreement with Botanix SB Inc., a subsidiary of the Botanix Pharmaceuticals Limited and it has […]

Continue Reading